Ocugen

OCGN

Market cap $362M

MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen will present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex in Boca Raton, FL.

Ocugen, Inc. ( OCGN ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Tiffany Hamilton - AVP & Head of Corporate Communications Shankar Musunuri - Co-Founder, CEO & Chairman Ramesh Ramachandran - Chief Accounting Officer, Principal Financial Officer & Principal Accounting Officer Huma Qamar - Chief Medical Officer Conference Call Participants Michael Okunewitch - Maxim Group LLC, Research Division Boris Peaker Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Elemer Piros - Lucid Capital Markets, LLC, Research Division Daniil Gataulin - Chardan Capital Markets, LLC, Research Division Presentation Operator Good morning, and welcome to Ocugen's Third Quarter 2025 Financial Results and Business Update.

Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.05 per share a year ago.

Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA) provided acceptability of a single U.S.-based trial for submission of a Marketing Authorization Application (MAA) Executed licensing agreement with Kwangdong Pharmaceutical for exclusive rights in South Korea to OCU400 Sales milestones of $1.5 million for every $15 million of sales in South Korea, projected to reach $180 million or more in first 10 years of commercialization and royalties equaling 25% of net sales Closed $20 million registered direct offering of common stock and accompanying premium warrants The Company will receive $30 million of additional gross proceeds if the warrants are exercised in full MALVERN, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported third quarter 2025 financial results along with a general business update.

MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, November 5, 2025.

Ocugen (OCGN) is a clinical-stage biotech focused on modifier gene therapies for inherited retinal diseases, with key catalysts expected by 2026. OCGN's pipeline includes OCU400 (RP/LCA), OCU410ST (Stargardt disease), and OCU410 (Geographic Atrophy), all addressing large unmet needs with no current cures. Recent FDA designations, strategic partnerships, and successful financings reduce dilution risk and position OCGN for pivotal trial readouts and regulatory filings over the next three years.

On Monday, investors clearly saw excellent value in the stock of Ocugen (OCGN 12.15%), a biotech that concentrates on treatments for eye disorders. They traded the company's shares up by more than 12%, on the back of a fresh licensing agreement signed with a peer in Asia.

Ocugen, Inc. OCGN shares traded higher on Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.

MALVERN, Pa., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today executed a licensing agreement with Kwangdong Pharmaceutical, Co., Ltd., (“Kwangdong”) one of the leading pharmaceutical companies in Korea, for the exclusive Korean rights to OCU400—Ocugen's novel modifier gene therapy for retinitis pigmentosa (RP).

MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen will participate in both a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference, September 8-10, 2025 in New York, NY and a spotlight panel titled “The FDA Gauntlet: Strategies for a Successful Run at Approval” during Biotech on Tap 2025, September 24-26, 2025 in Munich, Germany.